Complete list of publications

• 1

  21.10.2020

  Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany

  ; Moorkens, E. ; Barcina Lacosta, T. ; Vulto, A. ; Schulz, M. ; Gradl, G. ; Enners, S. ; Selke, G. ; Huys, I. ; Simoens, S.

  Pharmaceuticals 2020, 13, 324
  doi:10.3390/ph13100324

  Link zur Publikation

  Conflicts of interest: S.S., I.H. and A.G.V. have founded the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). S.S. was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD; he has participated in advisory board meetings for Pfizer and Amgen; he has contributed to studies on biologics and biosimilars for Hospira (together with A.G.V. and I.H.), Celltrion, Mundipharma and Pfizer, and he has had speaking engagements for Amgen and Sandoz. A.G.V. is involved in consulting, advisory work and speaking engagements for a number of companies, a.o. AbbVie, Accord, Amgen, Biogen, EGA, Pfizer/Hospira, Mundipharma, Roche, Sandoz. E.M., T.B.L., G.G., S.E., M.S. and G.S. declare no conflict of interest.

• 1

  19.10.2020

  Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany

  ; Rudolph, U. ; Enners, S. ; Kieble, M. ; Mahfoud, F. ; Böhm, M. ; Laufs, U. ; Schulz, M.

  J Hum Hypertens, 14.10.2020
  doi.org./10.1038/s41371-020-00425-z 

  Conflicts of interest: UR has received scientific support and speaker honoraria from Bayer, Berlin Chemie, and Bristol Myers Squibb, all outside the submitted work. FM is supported by Deutsche Gesellschaft für Kardiologie (DGK) and has received scientific support and speaker honoraria from Bayer, Boehringer Ingelheim, Medtronic, and ReCor Medical, all outside the submitted work. FM and MB are supported by the Deutsche Forschungsgemeinschaft (SFB TRR219). UL has received speaker honoraria from Bayer, Boehringer Ingelheim, Novartis and Servier, all outside the submitted work. MS has received speaker honoraria from Novartis and Sanofi, all outside the submitted work. All other authors declare no conflict of interest.

• 1

  08.10.2020

  “Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription

  ; Mahfoud, F. ; Kieble, M. ; Enners, S. ; Werning, J. ; Laufs, U. ; Millenaar, D. ; Böhm, M. ; Kintscher, U. ; Schulz, M.

  Dtsch Arztebl Int 2020; 117: 687–8.
  DOI: 10.3238/arztebl.2020.0687

  Link zur Publikation

  Conflicts of interest: Felix Mahfoud erhielt Forschungsunterstützung und Vortragshonorare von Medtronic, Recor, Berlin Chemie und Boehringer Ingelheim. Michael Böhm bekam Honorare für Beratertätigkeit von den Firmen Abott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Servier, Medtronic, Vifor, Novartis und Bristol Myers Squibb. Ulrich Kintscher erhielt Forschungsunterstützung und/oder Vortraghonorare von Bayer, Berlin Chemie, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Sanofi und Servier. Ulrich Laufs hat Vortragshonorare von Bayer, Boehringer Ingelheim, Novartis und Servier erhalten. Martin Schulz bekam Vortragshonorare von Novartis und Sanofi. Die übrigen Autoren erklären, dass kein Interessenkonflikt besteht.

• 1

  21.10.2019

  The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.

  ; Hofmann, G. ; Gradl, G. ; Schulz, M. ; Haidinger, G. ; Tanew, A. ; Weber, B.

  J Eur Acad Dermatol Venereol. 2019 Sep 14. doi: 10.1111/jdv.15952

  Conflicts of interest: None declared.

• 1

  21.10.2019

  Post-mortem analysis of prescription opioids - A follow-up examination by LC–MS/MS with focus on fentanyl

  ; Schönfeld, T. ; Heinemann, A. ; Schulz, M. ; Gradl, G. ; Andresen-Streichert, H. ; Müller, A. ; Iwersen-Bergmann, S.

  Forensic Sci Int. 2019 Oct 9;305:109970. doi: 10.1016/j.forsciint.2019.109970

  Conflicts of interest: None declared

• 1

  14.12.2018

  Fixkombinationen von Antihypertensiva auf dem deutschen Markt - Fixkombinationen von ACE-Hemmern, Angiotensin-II-Rezeptorblockern, Betablockern, Calciumkanalblockern und Diuretika

  ; Kieble, M. ; Enners, S. ; Schulz, M.

  Fixkombinationen von Antihypertensiva auf dem deutschen Markt_DAPI_Stand 15.11.2018

  Conflicts of interest: none declared.

• 1

  28.09.2018

  Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016

  ; Gradl, G. ; Teichert, M. ; Kieble, M. ; Werning, J. ; Schulz, M.

  KEYWORDS
  ambulatory care, anti‐bacterial agents, drug utilization, Germany, Netherlands,
  pharmacoepidemiology

  Pharmacoepidemiol Drug Saf. 2018;1–12. doi: 10.1002/pds.4643

  Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016

  Conflicts of interest: None declared

• 1

  30.05.2018

  Extemporaneous formulations in Germany - relevance for everyday clinical practice.

  ; Staubach-Renz, P. ; Salzmann, S. ; Peveling-Oberhag, A. ; Weyer, V. ; Zimmer, S. ; Gradl, G. ; Lang, B.

  J Dtsch Dermatol Ges. 2018 May;16(5):566-574. doi: 10.1111/ddg.13519.

  www.ncbi.nlm.nih.gov/pubmed/29750454

   

  Conflicts of interest: None declared

• 1

  15.01.2018

  In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review.

  ; Krüger, K. ; Griese-Mammen, N. ; Schubert, I. ; Kieble, M. ; Botermann, L. ; Laufs, U. ; Kloft, C. ; Schulz, M.

  Heart Fail Rev - 2018 Jan;23(1):63-71

  www.ncbi.nlm.nih.gov/pubmed/28993930

  Conflicts of interest: None declared

• 1

  16.10.2017

  Oral Antibiotics in Germany and the Netherlands in Primary Care from 2012 – 2016: A Comparison

  ; Gradl, G. ; Teichert, M. ; Kieble, M. ; Werning, J. ; Schulz, M.

  Poster 46th ESCP Symposium on Clinical Pharmacy (Best Poster Award).
  Heidelberg, 09.-11.10.2017. Programme and Abstract Book PE007, p. 166
  Int. J. Clin. Pharm. 40, 1 (2018) 295.

   

   

  ESCP-2017_Poster_PE007_Oral_antibiotics

  Conflicts of interest: None declared